Solventum Corporation (SOLV)
Here's Why Solventum (SOLV) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Solventum Q2 Earnings Call Highlights
Solventum NYSE: SOLV reported second-quarter results that exceeded its internal expectations, supported by broad-based segment performance, planned order activity ahead of an ERP cutover and a tariff refund benefit. The company also announced plans to separate its Health Information Systems, or HIS, business as part of a broader effort to sharpen its focus on medical technology markets.
Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
SOLV's Q2 earnings and revenues beat estimates as organic sales increase 9.5%, prompting higher 2026 guidance despite ERP timing benefits.
Solventum Corporation (SOLV) Q2 2026 Earnings Call Transcript
Solventum Corporation (SOLV) Q2 2026 Earnings Call Transcript
Solventum (SOLV) Q2 Earnings and Revenues Top Estimates
Solventum (SOLV) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $1.69 per share a year ago.
Solventum (SOLV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Solventum (SOLV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Solventum to Report Q2 Earnings: What's in Store for the Stock?
SOLV's Q2 results are likely to benefit from segment strength, Acera gains and cost savings, offset by tariffs and ERP-related sales timing shifts.
Nelson Peltz and Trian Take a New Position: The Turnaround Thesis
Nelson Peltz's Trian Fund Management has emerged as the largest institutional shareholder of Solventum (NYSE:SOLV | SOLV Price Prediction), holding 7.09 million shares, or roughly 4.75% of outstanding stock.
Why Solventum (SOLV) is a Top Stock for the Long-Term
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
SOLV's innovation, cost savings and strong segment demand support growth, while raw material cost increases remain a key risk.
Earnings Growth & Price Strength Make Solventum (SOLV) a Stock to Watch
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Solving A Lackluster Growth Outlook Should Be Solventum's Next Priority
Solventum Corporation continues to trade at a noticeable discount, with shares showing resilience versus med-tech peers despite tepid growth expectations. Management targets 3–4% underlying revenue growth for 2026, with SOLV EPS likely at the high end of the $6.40–$6.60 range. Restructuring and portfolio optimization offer significant upside, as SOLV's business units lack natural synergies and could be divested.
